Siemens Healthineers Slides as Investors Weigh Imaging Momentum Against Pending Accela Clearance
Published on 10/01/2026 at 07:50 | Editorial boerse-global.de
Siemens Healthineers shares have run into a patch of turbulence just as the market was banking on an autumn rebound. The stock shed 2.1% in the previous session to close at EUR 37.83, with media reports pointing to no company-specific trigger behind the selling. Instead, the DAX-listed medical technology group was dragged down by a broader market mood soured by weak eurozone inflation figures and fresh worries about interest rates.
The pullback continued into the next trading day, when the stock gave up another 1.2% to change hands at EUR 38.16. That softness has left investors asking a familiar question: is this a buying window, or the start of a deeper slide? For a sector as capital-intensive as medical technology, the answer often lies less with the company itself than with the rate cycle.
Imaging Holds the Key to Full-Year Targets
What happens next on the operating front hinges largely on one division. Imaging is the group's backbone, reliably throwing off a hefty share of earnings, and management is counting on a visible acceleration there in the final quarter to bring its full-year goals within reach. Organic revenue growth of up to 4% is on the table for the current fiscal year, while Jefferies pencils in adjusted earnings per share of between EUR 2.35 and EUR 2.45 — squarely in line with consensus.
The expected year-end sprint should be powered by Imaging, where revenue pushed out of the prior quarter and a steady scanner business ought to provide lift. Precision therapy is also forecast to advance, though the diagnostics unit is still seen contracting. At the operating margin level, a sequential improvement looks likely, even if persistent cost pressure could take some of the shine off the gains.
Beyond the next few weeks, the case for a lasting re-rating rests on signals for fiscal 2027. Jefferies models adjusted EPS of EUR 2.30 to EUR 2.40 for that year, with potential tariff headwinds expected to be largely offset by cost savings. Market watchers say the group needs more than that: a genuine pickup in Chinese demand and clarity on the diagnostics business — where a sale or spin-off remains on the table — are seen as the missing pieces.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Analysts Stay Bullish, With One Eye on Accela
Sell-side sentiment remains firmly constructive. Jefferies reiterated its "Buy" rating with a EUR 50 price target, with analyst Julien Dormois flagging clear signs of gathering momentum in Imaging and expressing confidence that the company will hit its annual objectives. JPMorgan added its own vote of confidence, with analyst David Adlington maintaining an "Overweight" rating and a EUR 57.40 target.
Adlington's optimism leans heavily on Accela, the new radio-oncology platform that Siemens Healthineers unveiled to specialists on Sunday. Built on NeoArc technology, the system is designed to deliver multi-target stereotactic radiation therapy in just 60 seconds. If the company can cement a technological lead in this niche, it could underwrite revenue growth down the road.
Commercial Rollout Still Pending
For all the enthusiasm, Accela remains a promise rather than a product. The 510(k) clearance that would open the crucial US market has yet to arrive, and the system is not commercially available in any market today. That means no near-term revenue contribution is on the cards.
Macro conditions add another layer of caution. When rate anxiety grips European markets, investors tend to steer clear of capital-hungry technology and healthcare names. On top of that sits the risk of operational delays: should customers postpone decisions on expensive large-scale equipment, the final-quarter momentum could fall short of hopes, forcing downward revisions to expectations for the coming fiscal year as well.
November 5 Sets the Direction
Two paths now lie open. If the share price holds its current level and operating signals reinforce confidence in Imaging, the road toward the analysts' price targets stays clear. But if broader market sentiment deteriorates further under sustained rate pressure, or if order intake in the closing quarter disappoints, renewed selling could follow.
The decisive catalyst arrives via the financial calendar. According to the company's schedule, Siemens Healthineers will publish fourth-quarter and full-year results on November 5, 2026. Management will use the subsequent analyst call not only to account for the year just ended but to set out its outlook for what comes next. Until then, macroeconomic forces and any news on the Accela clearance are likely to dictate the tempo on the trading floor.
The stock has lost 15% since the start of the year, trailing the wider market — a reminder that the hoped-for growth acceleration still has to prove itself.
Ad
Siemens Healthineers Stock: New Analysis - 1 October
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
